CLINICAL STUDY

Ovary volume: The left ovary volume of the study population was significantly decreased up to 23.78% till the completion of the treatment (p-value 0.0001**). Similarly, right ovary volume was also reduced significantly up to 29.32% till the completion of the treatment (p-value 0.0001**). The left ovary volume was decreased in 90% of the patients and right ovary volume was decreased in 96.7% of subjects.

Cyst size: The mean cyst size in the right ovary of the study population was significantly reduced up to 41.57% till the completion of the treatment (p-value 0.0001**). If we consider cyst size of the left ovaries, it was also decreased significantly up to 44.92% in the study population till completion of the treatment (0.0001**). Fifteen patients got pregnant during the study & complete dissolution of cysts was observed in 8 patients.

HOMA index: Being a major indicator of insulin resistance, HOMA index also shown to be significantly reduced up to 46.54% in 75.67% of the study population till the completion of the treatment (p-value 0.0001**).

Menstrual cycle: Menstrual cycle of the study population was regularized in most of the patients. Only 1.1% of study population had regular menstrual cycle at baseline and after 12 weeks of treatment with Furocyst, 79.5% of the study population had regular menstrual cycle.

Liver Function Test (LFT): There was no significant change in liver function test of the study population except ALT/SGPT activity which were slightly decreased significantly (p-value 0.007**) but remained under normal range on the completion of the treatment.

Renal function test (RFT): There was non-significant change in urea levels but creatinine levels changed significantly on the completion of the treatment (p-value 0.032*) and remained under normal range.

Hemogram: There was non-significant change in hemoglobin levels and differential leukocyte count (DLC) of the study population on the completion of the treatment. Total leukocyte count (TLC) of the study population significantly decreased slightly on completion of the treatment (p-value 0.002**).

Lipid profile: There was non-significant change in lipid profile including cholesterol levels and triglyceride levels of the study population whereas HDL levels of the study population increased significantly on completion of the treatment (p-value 0.030*).

Information on this website has been posted in public interest for creating awareness about Polycystic Ovarian Syndrome(PCOS). Links to the related original documents/sources of information have been provided, wherever possible to enable readers to get access to detailed information on Polycystic Ovarian Syndrome(PCOS), if required. In event of any copyright conflicts, please inform so that we may take appropriate remedial measures. The product and the claim made on this site has not been evaluated by FDA and is not approved to diagnose, treat, cure or prevent diseases.